---
---

# 21 U.S.C., USLM ref /us/usc/t21/ch9

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../..//us/usc/t21/ch8/m__us_usc_t21_s221 to 237.md) | [Next](./../../../..//us/usc/t21/ch9/schI/m__us_usc_t21_ch9_schI.md) | [Root of Title](./../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fch9)

## CHAPTER 9—FEDERAL FOOD, DRUG, AND COSMETIC ACT

<table>

  <tr>

    <td> 

SUBCHAPTER I—SHORT TITLE  </td>

  </tr>

  <tr>

    <td> Sec.  </td>

  </tr>

  <tr>

    <td> 301.  </td>

    <td> Short title.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER II—DEFINITIONS  </td>

  </tr>

  <tr>

    <td> 321.  </td>

    <td> Definitions; generally.  </td>

  </tr>

  <tr>

    <td> 321a.  </td>

    <td> “Butter” defined.  </td>

  </tr>

  <tr>

    <td> 321b.  </td>

    <td> “Package” defined.  </td>

  </tr>

  <tr>

    <td> 321c.  </td>

    <td> Nonfat dry milk; “milk” defined.  </td>

  </tr>

  <tr>

    <td> 321d.  </td>

    <td> Market names for catfish and ginseng.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER III—PROHIBITED ACTS AND PENALTIES  </td>

  </tr>

  <tr>

    <td> 331.  </td>

    <td> Prohibited acts.  </td>

  </tr>

  <tr>

    <td> 332.  </td>

    <td> Injunction proceedings.  </td>

  </tr>

  <tr>

    <td> 333.  </td>

    <td> Penalties.  </td>

  </tr>

  <tr>

    <td> 333a.  </td>

    <td> Repealed.  </td>

  </tr>

  <tr>

    <td> 334.  </td>

    <td> Seizure.  </td>

  </tr>

  <tr>

    <td> 335.  </td>

    <td> Hearing before report of criminal violation.  </td>

  </tr>

  <tr>

    <td> 335a.  </td>

    <td> Debarment, temporary denial of approval, and suspension.  </td>

  </tr>

  <tr>

    <td> 335b.  </td>

    <td> Civil penalties.  </td>

  </tr>

  <tr>

    <td> 335c.  </td>

    <td> Authority to withdraw approval of abbreviated drug applications.  </td>

  </tr>

  <tr>

    <td> 336.  </td>

    <td> Report of minor violations.  </td>

  </tr>

  <tr>

    <td> 337.  </td>

    <td> Proceedings in name of United States; provision as to subpoenas.  </td>

  </tr>

  <tr>

    <td> 337a.  </td>

    <td> Extraterritorial jurisdiction.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER IV—FOOD  </td>

  </tr>

  <tr>

    <td> 341.  </td>

    <td> Definitions and standards for food.  </td>

  </tr>

  <tr>

    <td> 342.  </td>

    <td> Adulterated food.  </td>

  </tr>

  <tr>

    <td> 343.  </td>

    <td> Misbranded food.  </td>

  </tr>

  <tr>

    <td> 343–1.  </td>

    <td> National uniform nutrition labeling.  </td>

  </tr>

  <tr>

    <td> 343–2.  </td>

    <td> Dietary supplement labeling exemptions.  </td>

  </tr>

  <tr>

    <td> 343–3.  </td>

    <td> Disclosure.  </td>

  </tr>

  <tr>

    <td> 343a.  </td>

    <td> Repealed.  </td>

  </tr>

  <tr>

    <td> 344.  </td>

    <td> Emergency permit control.  </td>

  </tr>

  <tr>

    <td> 345.  </td>

    <td> Regulations making exemptions.  </td>

  </tr>

  <tr>

    <td> 346.  </td>

    <td> Tolerances for poisonous or deleterious substances in food; regulations.  </td>

  </tr>

  <tr>

    <td> 346a.  </td>

    <td> Tolerances and exemptions for pesticide chemical residues.  </td>

  </tr>

  <tr>

    <td> 346b.  </td>

    <td> Authorization of appropriations.  </td>

  </tr>

  <tr>

    <td> 347.  </td>

    <td> Intrastate sales of colored oleomargarine.  </td>

  </tr>

  <tr>

    <td> 347a.  </td>

    <td> Congressional declaration of policy regarding oleomargarine sales.  </td>

  </tr>

  <tr>

    <td> 347b.  </td>

    <td> Contravention of State laws.  </td>

  </tr>

  <tr>

    <td> 348.  </td>

    <td> Food additives.  </td>

  </tr>

  <tr>

    <td> 349.  </td>

    <td> Bottled drinking water standards; publication in Federal Register.  </td>

  </tr>

  <tr>

    <td> 350.  </td>

    <td> Vitamins and minerals.  </td>

  </tr>

  <tr>

    <td> 350a.  </td>

    <td> Infant formulas.  </td>

  </tr>

  <tr>

    <td> 350b.  </td>

    <td> New dietary ingredients.  </td>

  </tr>

  <tr>

    <td> 350c.  </td>

    <td> Maintenance and inspection of records.  </td>

  </tr>

  <tr>

    <td> 350d.  </td>

    <td> Registration of food facilities.  </td>

  </tr>

  <tr>

    <td> 350e.  </td>

    <td> Sanitary transportation practices.  </td>

  </tr>

  <tr>

    <td> 350f.  </td>

    <td> Reportable food registry.  </td>

  </tr>

  <tr>

    <td> 350g.  </td>

    <td> Hazard analysis and risk-based preventive controls.  </td>

  </tr>

  <tr>

    <td> 350h.  </td>

    <td> Standards for produce safety.  </td>

  </tr>

  <tr>

    <td> 350i.  </td>

    <td> Protection against intentional adulteration.  </td>

  </tr>

  <tr>

    <td> 350j.  </td>

    <td> Targeting of inspection resources for domestic facilities, foreign facilities, and ports of entry; annual report.  </td>

  </tr>

  <tr>

    <td> 350k.  </td>

    <td> Laboratory accreditation for analyses of foods.  </td>

  </tr>

  <tr>

    <td> 350l.  </td>

    <td> Mandatory recall authority.  </td>

  </tr>

  <tr>

    <td> 350l–1.  </td>

    <td> Annual report to Congress.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER V—DRUGS AND DEVICES  </td>

  </tr>

  <tr>

    <td> 

Part A—Drugs and Devices  </td>

  </tr>

  <tr>

    <td> 351.  </td>

    <td> Adulterated drugs and devices.  </td>

  </tr>

  <tr>

    <td> 352.  </td>

    <td> Misbranded drugs and devices.  </td>

  </tr>

  <tr>

    <td> 353.  </td>

    <td> Exemptions and consideration for certain drugs, devices, and biological products.  </td>

  </tr>

  <tr>

    <td> 353a.  </td>

    <td> Pharmacy compounding.  </td>

  </tr>

  <tr>

    <td> 353b.  </td>

    <td> Prereview of television advertisements.  </td>

  </tr>

  <tr>

    <td> 354.  </td>

    <td> Veterinary feed directive drugs.  </td>

  </tr>

  <tr>

    <td> 355.  </td>

    <td> New drugs.  </td>

  </tr>

  <tr>

    <td> 355–1.  </td>

    <td> Risk evaluation and mitigation strategies.  </td>

  </tr>

  <tr>

    <td> 355a.  </td>

    <td> Pediatric studies of drugs.  </td>

  </tr>

  <tr>

    <td> 355b.  </td>

    <td> Adverse-event reporting.  </td>

  </tr>

  <tr>

    <td> 355c.  </td>

    <td> Research into pediatric uses for drugs and biological products.  </td>

  </tr>

  <tr>

    <td> 355c–1.  </td>

    <td> Report.  </td>

  </tr>

  <tr>

    <td> 355d.  </td>

    <td> Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers.  </td>

  </tr>

  <tr>

    <td> 355e.  </td>

    <td> Pharmaceutical security.  </td>

  </tr>

  <tr>

    <td> 355f.  </td>

    <td> Extension of exclusivity period for new qualified infectious disease products.  </td>

  </tr>

  <tr>

    <td> 356.  </td>

    <td> Expedited approval of drugs for serious or life-threatening diseases or conditions.  </td>

  </tr>

  <tr>

    <td> 356–1.  </td>

    <td> Accelerated approval of priority countermeasures.  </td>

  </tr>

  <tr>

    <td> 356a.  </td>

    <td> Manufacturing changes.  </td>

  </tr>

  <tr>

    <td> 356b.  </td>

    <td> Reports of postmarketing studies.  </td>

  </tr>

  <tr>

    <td> 356c.  </td>

    <td> Discontinuance or interruption in the production of life-saving drugs.  </td>

  </tr>

  <tr>

    <td> 356c–1.  </td>

    <td> Annual reporting on drug shortages.  </td>

  </tr>

  <tr>

    <td> 356d.  </td>

    <td> Coordination; task force and strategic plan.  </td>

  </tr>

  <tr>

    <td> 356e.  </td>

    <td> Drug shortage list.  </td>

  </tr>

  <tr>

    <td> 356f.  </td>

    <td> Hospital repackaging of drugs in shortage.  </td>

  </tr>

  <tr>

    <td> 357.  </td>

    <td> Repealed.  </td>

  </tr>

  <tr>

    <td> 358.  </td>

    <td> Authority to designate official names.  </td>

  </tr>

  <tr>

    <td> 359.  </td>

    <td> Nonapplicability of subchapter to cosmetics.  </td>

  </tr>

  <tr>

    <td> 360.  </td>

    <td> Registration of producers of drugs or devices.  </td>

  </tr>

  <tr>

    <td> 360a.  </td>

    <td> Clinical trial guidance for antibiotic drugs.  </td>

  </tr>

  <tr>

    <td> 360a–1.  </td>

    <td> Clinical trials.  </td>

  </tr>

  <tr>

    <td> 360b.  </td>

    <td> New animal drugs.  </td>

  </tr>

  <tr>

    <td> 360c.  </td>

    <td> Classification of devices intended for human use.  </td>

  </tr>

  <tr>

    <td> 360c–1.  </td>

    <td> Reporting.  </td>

  </tr>

  <tr>

    <td> 360d.  </td>

    <td> Performance standards.  </td>

  </tr>

  <tr>

    <td> 360e.  </td>

    <td> Premarket approval.  </td>

  </tr>

  <tr>

    <td> 360e–1.  </td>

    <td> Pediatric uses of devices.  </td>

  </tr>

  <tr>

    <td> 360f.  </td>

    <td> Banned devices.  </td>

  </tr>

  <tr>

    <td> 360g.  </td>

    <td> Judicial review.  </td>

  </tr>

  <tr>

    <td> 360g–1.  </td>

    <td> Agency documentation and review of significant decisions regarding devices.  </td>

  </tr>

  <tr>

    <td> 360h.  </td>

    <td> Notification and other remedies.  </td>

  </tr>

  <tr>

    <td> 360h–1.  </td>

    <td> Program to improve the device recall system.  </td>

  </tr>

  <tr>

    <td> 360i.  </td>

    <td> Records and reports on devices.  </td>

  </tr>

  <tr>

    <td> 360j.  </td>

    <td> General provisions respecting control of devices intended for human use.  </td>

  </tr>

  <tr>

    <td> 360k.  </td>

    <td> State and local requirements respecting devices.  </td>

  </tr>

  <tr>

    <td> 360l.  </td>

    <td> Postmarket surveillance.  </td>

  </tr>

  <tr>

    <td> 360m.  </td>

    <td> Accredited persons.  </td>

  </tr>

  <tr>

    <td> 360n.  </td>

    <td> Priority review to encourage treatments for tropical diseases.  </td>

  </tr>

  <tr>

    <td> 360n–1.  </td>

    <td> Priority review for qualified infectious disease products.  </td>

  </tr>

  <tr>

    <td> 

Part B—Drugs for Rare Diseases or Conditions  </td>

  </tr>

  <tr>

    <td> 360aa.  </td>

    <td> Recommendations for investigations of drugs for rare diseases or conditions.  </td>

  </tr>

  <tr>

    <td> 360bb.  </td>

    <td> Designation of drugs for rare diseases or conditions.  </td>

  </tr>

  <tr>

    <td> 360cc.  </td>

    <td> Protection for drugs for rare diseases or conditions.  </td>

  </tr>

  <tr>

    <td> 360dd.  </td>

    <td> Open protocols for investigations of drugs for rare diseases or conditions.  </td>

  </tr>

  <tr>

    <td> 360ee.  </td>

    <td> Grants and contracts for development of drugs for rare diseases and conditions.  </td>

  </tr>

  <tr>

    <td> 360ff.  </td>

    <td> Priority review to encourage treatments for rare pediatric diseases.  </td>

  </tr>

  <tr>

    <td> 

Part C—Electronic Product Radiation Control  </td>

  </tr>

  <tr>

    <td> 360hh.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 360ii.  </td>

    <td> Program of control.  </td>

  </tr>

  <tr>

    <td> 360jj.  </td>

    <td> Studies by Secretary.  </td>

  </tr>

  <tr>

    <td> 360kk.  </td>

    <td> Performance standards for electronic products.  </td>

  </tr>

  <tr>

    <td> 360ll.  </td>

    <td> Notification of defects in and repair or replacement of electronic products.  </td>

  </tr>

  <tr>

    <td> 360mm.  </td>

    <td> Imports.  </td>

  </tr>

  <tr>

    <td> 360nn.  </td>

    <td> Inspection, records, and reports.  </td>

  </tr>

  <tr>

    <td> 360oo.  </td>

    <td> Prohibited acts.  </td>

  </tr>

  <tr>

    <td> 360pp.  </td>

    <td> Enforcement.  </td>

  </tr>

  <tr>

    <td> 360qq.  </td>

    <td> Repealed.  </td>

  </tr>

  <tr>

    <td> 360rr.  </td>

    <td> Federal-State cooperation.  </td>

  </tr>

  <tr>

    <td> 360ss.  </td>

    <td> State standards.  </td>

  </tr>

  <tr>

    <td> 

Part D—Dissemination of Treatment Information  </td>

  </tr>

  <tr>

    <td> 360aaa to 360aaa–6. Omitted  </td>

  </tr>

  <tr>

    <td> 

Part E—General Provisions Relating to Drugs and Devices  </td>

  </tr>

  <tr>

    <td> 360bbb.  </td>

    <td> Expanded access to unapproved therapies and diagnostics.  </td>

  </tr>

  <tr>

    <td> 360bbb–1.  </td>

    <td> Dispute resolution.  </td>

  </tr>

  <tr>

    <td> 360bbb–2.  </td>

    <td> Classification of products.  </td>

  </tr>

  <tr>

    <td> 360bbb–3.  </td>

    <td> Authorization for medical products for use in emergencies.  </td>

  </tr>

  <tr>

    <td> 360bbb–3a.  </td>

    <td> Emergency use of medical products.  </td>

  </tr>

  <tr>

    <td> 360bbb–3b.  </td>

    <td> Products held for emergency use.  </td>

  </tr>

  <tr>

    <td> 360bbb–4.  </td>

    <td> Countermeasure development, review, and technical assistance.  </td>

  </tr>

  <tr>

    <td> 360bbb–5.  </td>

    <td> Critical Path Public-Private Partnerships.  </td>

  </tr>

  <tr>

    <td> 360bbb–6.  </td>

    <td> Risk communication.  </td>

  </tr>

  <tr>

    <td> 360bbb–7.  </td>

    <td> Notification.  </td>

  </tr>

  <tr>

    <td> 360bbb–8.  </td>

    <td> Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.  </td>

  </tr>

  <tr>

    <td> 360bbb–8a.  </td>

    <td> Optimizing global clinical trials.  </td>

  </tr>

  <tr>

    <td> 360bbb–8b.  </td>

    <td> Use of clinical investigation data from outside the United States.  </td>

  </tr>

  <tr>

    <td> 360bbb–8c.  </td>

    <td> Patient participation in medical product discussion.  </td>

  </tr>

  <tr>

    <td> 

Part F—New Animal Drugs for Minor Use and Minor Species  </td>

  </tr>

  <tr>

    <td> 360ccc.  </td>

    <td> Conditional approval of new animal drugs for minor use and minor species.  </td>

  </tr>

  <tr>

    <td> 360ccc–1.  </td>

    <td> Index of legally marketed unapproved new animal drugs for minor species.  </td>

  </tr>

  <tr>

    <td> 360ccc–2.  </td>

    <td> Designated new animal drugs for minor use or minor species.  </td>

  </tr>

  <tr>

    <td> 

Part G—Medical Gases  </td>

  </tr>

  <tr>

    <td> 360ddd.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 360ddd–1.  </td>

    <td> Regulation of medical gases.  </td>

  </tr>

  <tr>

    <td> 360ddd–2.  </td>

    <td> Inapplicability of drug fees to designated medical gases.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER VI—COSMETICS  </td>

  </tr>

  <tr>

    <td> 361.  </td>

    <td> Adulterated cosmetics.  </td>

  </tr>

  <tr>

    <td> 362.  </td>

    <td> Misbranded cosmetics.  </td>

  </tr>

  <tr>

    <td> 363.  </td>

    <td> Regulations making exemptions.  </td>

  </tr>

  <tr>

    <td> 364.  </td>

    <td> Repealed.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER VII—GENERAL AUTHORITY  </td>

  </tr>

  <tr>

    <td> 

Part A—General Administrative Provisions  </td>

  </tr>

  <tr>

    <td> 371.  </td>

    <td> Regulations and hearings.  </td>

  </tr>

  <tr>

    <td> 372.  </td>

    <td> Examinations and investigations.  </td>

  </tr>

  <tr>

    <td> 372a.  </td>

    <td> Transferred.  </td>

  </tr>

  <tr>

    <td> 373.  </td>

    <td> Records.  </td>

  </tr>

  <tr>

    <td> 374.  </td>

    <td> Inspection.  </td>

  </tr>

  <tr>

    <td> 374a.  </td>

    <td> Inspections relating to food allergens.  </td>

  </tr>

  <tr>

    <td> 375.  </td>

    <td> Publicity.  </td>

  </tr>

  <tr>

    <td> 376.  </td>

    <td> Examination of sea food on request of packer; marking food with results; fees; penalties.  </td>

  </tr>

  <tr>

    <td> 377.  </td>

    <td> Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests.  </td>

  </tr>

  <tr>

    <td> 378.  </td>

    <td> Advertising of foods.  </td>

  </tr>

  <tr>

    <td> 379.  </td>

    <td> Confidential information.  </td>

  </tr>

  <tr>

    <td> 379a.  </td>

    <td> Presumption of existence of jurisdiction.  </td>

  </tr>

  <tr>

    <td> 379b.  </td>

    <td> Consolidated administrative and laboratory facility.  </td>

  </tr>

  <tr>

    <td> 379c.  </td>

    <td> Transferred.  </td>

  </tr>

  <tr>

    <td> 379d.  </td>

    <td> Automation of Food and Drug Administration.  </td>

  </tr>

  <tr>

    <td> 379d–1.  </td>

    <td> Conflicts of interest.  </td>

  </tr>

  <tr>

    <td> 379d–2.  </td>

    <td> Policy on the review and clearance of scientific articles published by FDA employees.  </td>

  </tr>

  <tr>

    <td> 379d–3.  </td>

    <td> Streamlined hiring authority.  </td>

  </tr>

  <tr>

    <td> 379d–4.  </td>

    <td> Reporting requirements.  </td>

  </tr>

  <tr>

    <td> 379d–5.  </td>

    <td> Guidance document regarding product promotion using the Internet.  </td>

  </tr>

  <tr>

    <td> 

Part B—Colors  </td>

  </tr>

  <tr>

    <td> 379e.  </td>

    <td> Listing and certification of color additives for foods, drugs, devices, and cosmetics.  </td>

  </tr>

  <tr>

    <td> 

Part C—Fees  </td>

  </tr>

  <tr>

    <td> 

subpart 1—freedom of information fees  </td>

  </tr>

  <tr>

    <td> 379f.  </td>

    <td> Recovery and retention of fees for freedom of information requests.  </td>

  </tr>

  <tr>

    <td> 

subpart 2—fees relating to drugs  </td>

  </tr>

  <tr>

    <td> 379g.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 379h.  </td>

    <td> Authority to assess and use drug fees.  </td>

  </tr>

  <tr>

    <td> 379h–1.  </td>

    <td> Fees relating to advisory review of prescription-drug television advertising.  </td>

  </tr>

  <tr>

    <td> 379h–2.  </td>

    <td> Reauthorization; reporting requirements.  </td>

  </tr>

  <tr>

    <td> 

subpart 3—fees relating to devices  </td>

  </tr>

  <tr>

    <td> 379i.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 379j.  </td>

    <td> Authority to assess and use device fees.  </td>

  </tr>

  <tr>

    <td> 379j–1.  </td>

    <td> Reauthorization; reporting requirements.  </td>

  </tr>

  <tr>

    <td> 

subpart 4—fees relating to animal drugs  </td>

  </tr>

  <tr>

    <td> 379j–11.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 379j–12.  </td>

    <td> Authority to assess and use animal drug fees.  </td>

  </tr>

  <tr>

    <td> 379j–13.  </td>

    <td> Reauthorization; reporting requirements.  </td>

  </tr>

  <tr>

    <td> 

subpart 5—fees relating to generic new animal drugs  </td>

  </tr>

  <tr>

    <td> 379j–21.  </td>

    <td> Authority to assess and use generic new animal drug fees.  </td>

  </tr>

  <tr>

    <td> 379j–22.  </td>

    <td> Reauthorization; reporting requirements.  </td>

  </tr>

  <tr>

    <td> 

subpart 6—fees related to food  </td>

  </tr>

  <tr>

    <td> 379j–31.  </td>

    <td> Authority to collect and use fees.  </td>

  </tr>

  <tr>

    <td> 

subpart 7—fees relating to generic drugs  </td>

  </tr>

  <tr>

    <td> 379j–41.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 379j–42.  </td>

    <td> Authority to assess and use human generic drug fees.  </td>

  </tr>

  <tr>

    <td> 379j–43.  </td>

    <td> Reauthorization; reporting requirements.  </td>

  </tr>

  <tr>

    <td> 

subpart 8—fees relating to biosimilar biological products  </td>

  </tr>

  <tr>

    <td> 379j–51.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 379j–52.  </td>

    <td> Authority to assess and use biosimilar biological product fees.  </td>

  </tr>

  <tr>

    <td> 379j–53.  </td>

    <td> Reauthorization; reporting requirements.  </td>

  </tr>

  <tr>

    <td> 

Part D—Information and Education  </td>

  </tr>

  <tr>

    <td> 379k.  </td>

    <td> Information system.  </td>

  </tr>

  <tr>

    <td> 379k–1.  </td>

    <td> Electronic format for submissions.  </td>

  </tr>

  <tr>

    <td> 379l.  </td>

    <td> Education.  </td>

  </tr>

  <tr>

    <td> 

Part E—Environmental Impact Review  </td>

  </tr>

  <tr>

    <td> 379o.  </td>

    <td> Environmental impact.  </td>

  </tr>

  <tr>

    <td> 

Part F—National Uniformity for Nonprescription Drugs and Preemption for Labeling or Packaging of Cosmetics  </td>

  </tr>

  <tr>

    <td> 379r.  </td>

    <td> National uniformity for nonprescription drugs.  </td>

  </tr>

  <tr>

    <td> 379s.  </td>

    <td> Preemption for labeling or packaging of cosmetics.  </td>

  </tr>

  <tr>

    <td> 

Part G—Safety Reports  </td>

  </tr>

  <tr>

    <td> 379v.  </td>

    <td> Safety report disclaimers.  </td>

  </tr>

  <tr>

    <td> 

Part H—Serious Adverse Event Reports  </td>

  </tr>

  <tr>

    <td> 379aa.  </td>

    <td> Serious adverse event reporting for nonprescription drugs.  </td>

  </tr>

  <tr>

    <td> 379aa–1.  </td>

    <td> Serious adverse event reporting for dietary supplements.  </td>

  </tr>

  <tr>

    <td> 

Part I—Reagan-Udall Foundation for the Food and Drug Administration  </td>

  </tr>

  <tr>

    <td> 379dd.  </td>

    <td> Establishment and functions of the Foundation.  </td>

  </tr>

  <tr>

    <td> 379dd–1.  </td>

    <td> Location of Foundation.  </td>

  </tr>

  <tr>

    <td> 379dd–2.  </td>

    <td> Activities of the Food and Drug Administration.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER VIII—IMPORTS AND EXPORTS  </td>

  </tr>

  <tr>

    <td> 381.  </td>

    <td> Imports and exports.  </td>

  </tr>

  <tr>

    <td> 382.  </td>

    <td> Exports of certain unapproved products.  </td>

  </tr>

  <tr>

    <td> 383.  </td>

    <td> Office of International Relations.  </td>

  </tr>

  <tr>

    <td> 384.  </td>

    <td> Importation of prescription drugs.  </td>

  </tr>

  <tr>

    <td> 384a.  </td>

    <td> Foreign supplier verification program.  </td>

  </tr>

  <tr>

    <td> 384b.  </td>

    <td> Voluntary qualified importer program.  </td>

  </tr>

  <tr>

    <td> 384c.  </td>

    <td> Inspection of foreign food facilities.  </td>

  </tr>

  <tr>

    <td> 384d.  </td>

    <td> Accreditation of third-party auditors.  </td>

  </tr>

  <tr>

    <td> 384e.  </td>

    <td> Recognition of foreign government inspections.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER IX—TOBACCO PRODUCTS  </td>

  </tr>

  <tr>

    <td> 387.  </td>

    <td> Definitions.  </td>

  </tr>

  <tr>

    <td> 387a.  </td>

    <td> FDA authority over tobacco products.  </td>

  </tr>

  <tr>

    <td> 387a–1.  </td>

    <td> Final rule.  </td>

  </tr>

  <tr>

    <td> 387b.  </td>

    <td> Adulterated tobacco products.  </td>

  </tr>

  <tr>

    <td> 387c.  </td>

    <td> Misbranded tobacco products.  </td>

  </tr>

  <tr>

    <td> 387d.  </td>

    <td> Submission of health information to the Secretary.  </td>

  </tr>

  <tr>

    <td> 387e.  </td>

    <td> Annual registration.  </td>

  </tr>

  <tr>

    <td> 387f.  </td>

    <td> General provisions respecting control of tobacco products.  </td>

  </tr>

  <tr>

    <td> 387f–1.  </td>

    <td> Enforcement action plan for advertising and promotion restrictions.  </td>

  </tr>

  <tr>

    <td> 387g.  </td>

    <td> Tobacco product standards.  </td>

  </tr>

  <tr>

    <td> 387h.  </td>

    <td> Notification and other remedies.  </td>

  </tr>

  <tr>

    <td> 387i.  </td>

    <td> Records and reports on tobacco products.  </td>

  </tr>

  <tr>

    <td> 387j.  </td>

    <td> Application for review of certain tobacco products.  </td>

  </tr>

  <tr>

    <td> 387k.  </td>

    <td> Modified risk tobacco products.  </td>

  </tr>

  <tr>

    <td> 387l.  </td>

    <td> Judicial review.  </td>

  </tr>

  <tr>

    <td> 387m.  </td>

    <td> Equal treatment of retail outlets.  </td>

  </tr>

  <tr>

    <td> 387n.  </td>

    <td> Jurisdiction of and coordination with the Federal Trade Commission.  </td>

  </tr>

  <tr>

    <td> 387o.  </td>

    <td> Regulation requirement.  </td>

  </tr>

  <tr>

    <td> 387p.  </td>

    <td> Preservation of State and local authority.  </td>

  </tr>

  <tr>

    <td> 387q.  </td>

    <td> Tobacco Products Scientific Advisory Committee.  </td>

  </tr>

  <tr>

    <td> 387r.  </td>

    <td> Drug products used to treat tobacco dependence.  </td>

  </tr>

  <tr>

    <td> 387s.  </td>

    <td> User fees.  </td>

  </tr>

  <tr>

    <td> 387t.  </td>

    <td> Labeling, recordkeeping, records inspection.  </td>

  </tr>

  <tr>

    <td> 387u.  </td>

    <td> Studies of progress and effectiveness.  </td>

  </tr>

  <tr>

    <td> 

SUBCHAPTER X—MISCELLANEOUS  </td>

  </tr>

  <tr>

    <td> 391.  </td>

    <td> Separability clause.  </td>

  </tr>

  <tr>

    <td> 392.  </td>

    <td> Exemption of meats and meat food products.  </td>

  </tr>

  <tr>

    <td> 393.  </td>

    <td> Food and Drug Administration.  </td>

  </tr>

  <tr>

    <td> 393a.  </td>

    <td> Office of Pediatric Therapeutics.  </td>

  </tr>

  <tr>

    <td> 394.  </td>

    <td> Scientific review groups.  </td>

  </tr>

  <tr>

    <td> 395.  </td>

    <td> Loan repayment program.  </td>

  </tr>

  <tr>

    <td> 396.  </td>

    <td> Practice of medicine.  </td>

  </tr>

  <tr>

    <td> 397.  </td>

    <td> Contracts for expert review.  </td>

  </tr>

  <tr>

    <td> 398.  </td>

    <td> Notices to States regarding imported food.  </td>

  </tr>

  <tr>

    <td> 399.  </td>

    <td> Grants to enhance food safety.  </td>

  </tr>

  <tr>

    <td> 399a.  </td>

    <td> Office of the Chief Scientist.  </td>

  </tr>

  <tr>

    <td> 399b.  </td>

    <td> Office of Women’s Health.  </td>

  </tr>

  <tr>

    <td> 399c.  </td>

    <td> Improving the training of State, local, territorial, and tribal food safety officials.  </td>

  </tr>

  <tr>

    <td> 399d.  </td>

    <td> Employee protections.  </td>

  </tr>

  <tr>

    <td> 399e.  </td>

    <td> Nanotechnology.  </td>

  </tr>

  <tr>

    <td> 399f.  </td>

    <td> Ensuring adequate information regarding pharmaceuticals for all populations, particularly underrepresented subpopulations, including racial subgroups.  </td>

  </tr>

</table>

----------

[Previous](./../../../..//us/usc/t21/ch8/m__us_usc_t21_s221 to 237.md) | [Next](./../../../..//us/usc/t21/ch9/schI/m__us_usc_t21_ch9_schI.md) | [Root of Title](./../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fch9)

----------
----------



